Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
522 studies found for:    lupus
Show Display Options
Rank Status Study
21 Recruiting Prospective Evaluation of Decision and Compliance With Antimalarials in Patients With Systemic Lupus
Condition: Systemic Lupus Erythematosus
Intervention: Other: therapeutic education
22 Recruiting Comparison Between Tacrolimus (TAC) and Mycophenolate Mofetil (MMF) for Induction of Remission in Lupus Nephritis
Condition: Lupus Nephritis
Intervention: Drug: Tacrolimus vs. Mycophenolate mofetil for Induction Therapy in Lupus Nephritis
23 Recruiting A Study of Skin and Systemic Biomarkers In Patients With Active Cutaneous Lupus Erythematosus And In Healthy Volunteers
Conditions: Lupus Erythematosus, Cutaneous;   Lupus Erythematosus, Systemic;   Lupus Erythematosus, Discoid;   Healthy
Interventions: Procedure: Skin biopsy;   Procedure: Blood collection;   Procedure: Urine collection
24 Withdrawn Velcade for Proliferative Lupus Nephritis
Conditions: Lupus Nephritis;   Proteinuria;   Hematuria
Intervention: Drug: Velcade
25 Recruiting The Research Registry for Neonatal Lupus
Conditions: Neonatal Lupus;   Systemic Lupus Erythematosus;   Sjogren's Syndrome;   Congenital Heart Block
Intervention: Other: No intervention; observational
26 Completed Safety and Efficacy Study of LJP 394 (Abetimus Sodium) to Treat Lupus Kidney Disease
Conditions: Immunologic Diseases;   Autoimmune Diseases;   Systemic Lupus Erythematosus;   Lupus Nephritis;   Lupus Glomerulonephritis
Intervention: Drug: Abetimus sodium (LJP 394)
27 Terminated Vitamin D Status, Disease Specific and Quality of Life Outcomes in Patients With Cutaneous Lupus
Condition: Cutaneous Lupus Erythematosus
Intervention: Dietary Supplement: vitamin D
28 Terminated Study of TRU-015 in Subjects With Membranous Nephropathy Secondary to Systemic Lupus Erythematosus
Condition: Systemic Lupus Erythematosus
Intervention: Drug: TRU-015
29 Withdrawn Clinical Trial Treatment in Lupus Nephritis
Condition: Lupus Nephritis
Interventions: Drug: cyclosporine +mycophenolic acid+prednison;   Drug: Mycophenolic Acid + prednison
30 Unknown  Mesenchymal Stem Cells Transplantation for Refractory Systemic Lupus Erythematosus (SLE)
Condition: Refractory Systemic Lupus Erythematosus
Intervention: Biological: Allogeneic MSC (AlloMSC)
31 Completed
Has Results
A Study to Evaluate the Safety of Rituximab Retreatment in Subjects With Systemic Lupus Erythematosus
Condition: Lupus Erythematosus, Systemic
Interventions: Drug: Rituximab;   Drug: Placebo;   Drug: Prednisone;   Drug: Acetaminophen;   Drug: Diphenhydramine
32 Completed Long-Acting Tacrolimus for the Treatment of Resistant Lupus Nephritis
Condition: Lupus Nephritis
Intervention: Drug: Long-acting tacrolimus (Advagraf, Astellas Pharma)
33 Completed Phase 3 Study of Tacrolimus (FK506) for Lupus Nephritis: A Placebo Controlled, Double-Blind Multicenter, Comparative Study
Condition: Lupus Nephritis
Intervention: Drug: tacrolimus
34 Recruiting Duke Lupus Registry
Conditions: Systemic Lupus Erythematosus;   Cutaneous Lupus
Intervention:
35 Recruiting Comparison of the Efficacy of Two Rituximab Treatment Regimens in Patients With Lupus Nephropathy
Condition: Lupus Nephritis
Intervention: Biological: Rituximab
36 Recruiting Individualized Patient Decision Making for Treatment Choices Among Minorities With Lupus
Condition: Systemic Lupus Erythematosus
Interventions: Other: computerized patient decision guide;   Other: usual care
37 Recruiting AURA-LV: Aurinia Urinary Protein Reduction Active - Lupus With Voclosporin
Condition: Lupus Nephritis
Interventions: Drug: Voclosporin High Dose;   Drug: Voclosporin Low Dose;   Drug: Placebo
38 Recruiting The Effect of Calcitriol on Progress and Activity of Lupus Nephritis
Condition: Systemic Lupus Erythematosus
Interventions: Drug: calcitriol;   Drug: placebo
39 Completed To Evaluate the Preliminary Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of CC-11050 in Subjects With Discoid Lupus Erythematosus and Subacute Cutaneous Lupus Erythematosus
Condition: Cutaneous Lupus Erythematosus
Intervention: Drug: CC-11050
40 Active, not recruiting Dipyridamole Assessment for Flare Reduction in Systemic Lupus Erythematosus (SLE)
Condition: Systemic Lupus Erythematosus
Interventions: Drug: extended release dipyridamole 200mg/aspirin 25mg;   Drug: 81mg aspirin

First Page    Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-60) Show next page of results    Last Page
Indicates status has not been verified in more than two years